Presented by Edinburgh University, Journal of Parkinson’s Disease and Cure Parkinson’s, the latest instalment of this quarterly webinar series discussed clinical trials targeting alpha-synuclein, with Edinburgh University’s Professor Tilo Kunath as chair. 

Professor Kunath was joined by: Gennaro Pagano, Expert Medical Director & Group Leader from Roche Pharma Research; Carroll Siu, person living with Parkinson’s and advisor to biopharmaceutical company UCB, on clinical outcomes; and Hilal Lashuel, Associate Professor of Life Sciences and Director of the Laboratory of Chemical Biology of Neurodegeneration, Brain Mind Institute.

Professor Kunath and the panel of experts in the field of alpha-synuclein research answered questions such as:

What is alpha-syunclein, what does it do, and why does it aggregate in Parkinson’s?

Are there different types of alpha-synuclein?

Is alpha-synuclein the right target in seeking to slow the progression of Parkinson’s?

What does the clinical trials landscape look like for targeting alpha-synuclein?

How helpful was this content?

/ 5. Vote count:

We are sorry that this content was not useful for you

Let us improve this content

Can you tell us how we can improve this content?